Genomics Market - By Product Type: Instruments, Reagents & Consumables, Services; By Technology: PCR, Sequencing, Microarray, Nucleic Acid Extraction, Others; By Application: Diagnostics, Drug Discovery, Agriculture, Research, Others; By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
The genomics industry has transformed from a USD 12.1 billion market in 2019 to a projected USD 23.8 billion in 2024, driven by declining sequencing costs (USD 500 per genome compared to USD 1,000 in 2019) and pandemic-driven surveillance needs. With CRISPR therapies entering Phase III trials and AI-driven drug discovery accelerating, the market is projected to reach USD 54.2 billion by 2031, growing at a CAGR of 14.2%. The clinical oncology segment now accounts for 38% of revenue, while direct-to-consumer testing faces regulatory challenges.
Key Data Points
|
Segment |
2024 Size |
2031 Projection |
CAGR |
|
Clinical Diagnostics |
USD 9.1B |
USD 22.3B |
16.4% |
|
Drug Discovery |
USD 6.8B |
USD 14.7B |
13.1% |
|
AgriGenomics |
USD 4.2B |
USD 9.8B |
12.8% |
Enhanced Research Content
Technology Breakthroughs
Competitive Landscape
|
Company |
Focus Area |
2024 Revenue |
|
Illumina |
Sequencing |
USD 5.2B |
|
CRISPR Tx |
Gene Editing |
USD 1.8B |
|
10x Genomics |
Spatial Biology |
USD 980M |
Recent Developments:
Need help?
Chat with our team in a minute.